PMID-28910237 – EXSCEL Exenatide Cardiovascular Outcomes Trial
Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-1239.
Quick Reference
| Property | Value |
|---|---|
| PMID | 28910237 |
| DOI | 10.1056/NEJMoa1612917 |
| Year | 2017 |
| Journal | New England Journal of Medicine |
| Study Type | RCT (cardiovascular outcomes trial) |
| Evidence Level | I |
| Sample | n=14,752 patients with type 2 diabetes (73.1% with prior CVD) |
| Peptide(s) Studied | Exenatide |
Key Findings
- Primary composite outcome (CV death, nonfatal MI, nonfatal stroke) occurred in 11.4% of exenatide group vs. 12.2% of placebo group (HR 0.91; 95% CI 0.83-1.00)
- Exenatide was noninferior to placebo for cardiovascular safety (P<0.001 for noninferiority) but did not achieve superiority (P=0.06)
- All-cause mortality was 6.9% vs. 7.6% (HR 0.86; 95% CI 0.77-0.97), nominally significant but not tested hierarchically
- Median follow-up of 3.2 years across 35 countries
- No increased risk of pancreatitis, pancreatic cancer, or medullary thyroid carcinoma
Study Design
Academically led, phase III/IV, double-blind, placebo-controlled, pragmatic trial. Patients were randomized 1:1 to extended-release exenatide 2 mg subcutaneously once weekly vs. placebo, added to usual care. Primary endpoint was first occurrence of 3-point MACE. The trial was event-driven with a planned 1360 events.
Limitations
- Pragmatic design with broad inclusion criteria may have diluted treatment effects
- High discontinuation rate (~43% in both groups)
- Median follow-up (3.2 years) shorter than some other GLP-1 RA CVOTs
- The trial was designed for noninferiority and may have been underpowered for superiority
Clinical Relevance
EXSCEL established cardiovascular safety of extended-release exenatide in a broad T2D population. While it did not demonstrate CV superiority like some later GLP-1 RAs (liraglutide/LEADER, semaglutide/SUSTAIN-6), the trend toward benefit and the nominal all-cause mortality reduction suggest possible cardioprotection. The pragmatic design and high event rate population make it relevant to real-world practice.
Related
#research #RCT #evidence-level-I #metabolic #exenatide